NASAL DEVICES

• US 20160279357A1
• Filed: 11/02/2015
• Published: 09/29/2016
• Est. Priority Date: 06/12/2001
• Status: Abandoned Application

• Current Assignee: OptiNose AS (OptiNose, Inc.)
• Original Assignee: OptiNose AS (OptiNose, Inc.)
• Inventors: Djupesland, Per Gisle
• Application Number:
  US14/929,489
• Publication Number:
  US 20160279357A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61M 15/0021 Mouthpieces therefor
• CPC Class Codes: A61M 15/0091 mechanically breath-triggered
• CPC Class Codes: A61M 15/0098 Activated by exhalation
• CPC Class Codes: A61M 15/08 Inhaling devices inserted into the nose
• CPC Class Codes: A61M 2202/064 Powder
• CPC Class Codes: A61M 2210/0618 Nose
• CPC Class Codes: A61M 2210/0625 Mouth
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14

Abstract

A nasal delivery device for and a method of delivering a substance, in particular one of a liquid, as a suspension or solution, or a powder containing a medicament, especially systemic or topical pharmaceuticals, or a vaccine to the nasal airway of a subject.

Claims

1-403. -403. (canceled)

404. A nasal delivery device for delivering a substance to a nasal airway of a subject, comprising:

a nosepiece unit configured to fit in a nostril of the subject, the nosepiece unit including a nozzle through which the substance is delivered to the nasal airway of the subject;

a mouthpiece unit configured to fit in a mouth of the subject and receive a flow of exhalation breath from the subject, whereby exhalation by the subject causes closure of a oropharyngeal velum of the subject;

a flow channel fluidly connecting the nosepiece unit and the mouthpiece unit, whereby exhalation breath flows from the mouthpiece unit through the fluid channel and out of the nosepiece unit;

at least one cuff member, which includes at least one lobe, configured to extend into a region of the nasal cavity of the subject and engage an inner wall of the nasal cavity of the subject when fitted in the nasal cavity of the subject; and

a delivery unit for delivering the substance through the nozzle of the nosepiece unit.

405. The delivery device of claim 404, wherein the substance is a powder.

406. The delivery device of claim 405, wherein the powder is a pharmaceutical.

407. The delivery device of claim 406, wherein the powder is an anti-migraine composition.

408. The delivery device of claim 404, wherein the substance is delivered to a site within the nasal airway of the subject.

409. The delivery device of claim 408, wherein the site includes at least a part of the inferior meatus.

410. The delivery device of claim 408, wherein the site includes at least a part of the middle meatus.

411. The delivery device of claim 408, wherein the site includes an inferior part of the middle meatus.

412. The delivery device of claim 408, wherein the site includes at least a part of the superior meatus.

413. The delivery device of claim 408, wherein the site includes at least a part of the inferior nasal concha.

414. The delivery device of claim 408, wherein the site includes at least a part of the middle nasal concha.

415. The delivery device of claim 408, wherein the site includes at least a part of the superior nasal concha.

416. The delivery device of claim 408, wherein the site includes at least a part of the olfactory region.

417. The delivery device of claim 408, wherein the site includes at least a sinus ostia.

418. The delivery device of claim 408, wherein the site includes at a least sinus infundibulum.

419. The delivery device of claim 408, wherein the site includes at least a part of the epipharynx.

420. The delivery device of claim 408, wherein the site includes at least adenoids.

421. The delivery device of claim 408, wherein the site includes at least tubal ostia.

422. The delivery device of claim 404, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μ

m to about 80 μ

m.

423. The delivery device of claim 404, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μ

m to about 50 μ

m.

424. The delivery device of claim 404, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μ

m to about 30 μ

m.

425. The delivery device of claim 404, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 10 μ

m to about 30 μ

m.

426. The delivery device of claim 404, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 10 μ

m to about 20 μ

m.

427. The delivery device of claim 404, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 15 μ

m to about 30 μ

m.

428. The delivery device of claim 404, wherein the nosepiece is a replaceable unit.

429. The delivery device of claim 404, wherein the at least one cuff member includes a plurality of lobes, the at least one cuff member configured to at least partially block the nasal cavity of the subject.

430. The delivery device of claim 404, wherein the delivery unit is configured to deliver the substance to the nozzle in response to the flow of exhalation breath.

431. A nasal delivery device for delivering a substance to a nasal airway of a subject, comprising:

a nosepiece unit configured to fit in a nostril of the subject, the nosepiece unit including a nozzle through which the substance is delivered to the nasal airway of the subject;

a mouthpiece unit configured to fit in a mouth of the subject and receive a flow of exhalation breath from the subject, whereby exhalation by the subject causes closure of a oropharyngeal velum of the subject;

a flow channel fluidly connecting the nosepiece unit and the mouthpiece unit, whereby exhalation breath flows from the mouthpiece unit through the fluid channel and out of the nosepiece unit; and

a delivery unit for delivering the substance through the nozzle of the nosepiece unit;

wherein the substance is a powder, a pharmaceutical, and an anti-migraine composition.

432. The delivery device of claim 431, wherein the substance is delivered to a site within the nasal airway of the subject.

433. The delivery device of claim 432, wherein the site includes at least a part of the inferior meatus.

434. The delivery device of claim 432, wherein the site includes at least a part of the middle meatus.

435. The delivery device of claim 432, wherein the site includes an inferior part of the middle meatus.

436. The delivery device of claim 432, wherein the site includes at least a part of the superior meatus.

437. The delivery device of claim 432, wherein the site includes at least a part of the inferior nasal concha.

438. The delivery device of claim 432, wherein the site includes at least a part of the middle nasal concha.

439. The delivery device of claim 432, wherein the site includes at least a part of the superior nasal concha.

440. The delivery device of claim 432, wherein the site includes at least a part of the olfactory region.

441. The delivery device of claim 432, wherein the site includes at least a sinus ostia.

442. The delivery device of claim 432, wherein the site includes at a least sinus infundibulum.

443. The delivery device of claim 432, wherein the site includes at least a part of the epipharynx.

444. The delivery device of claim 432, wherein the site includes at least adenoids.

445. The delivery device of claim 432, wherein the site includes at least tubal ostia.

446. The delivery device of claim 431, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μ

m to about 80 μ

m.

447. The delivery device of claim 431, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μ

m to about 50 μ

m.

448. The delivery device of claim 431, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μ

m to about 30 μ

m.

449. The delivery device of claim 431, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 10 μ

m to about 30 μ

m.

450. The delivery device of claim 431, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 10 μ

m to about 20 μ

m.

451. The delivery device of claim 431, wherein more than half of the particles in a particle size distribution of the substance are in the range of about 15 μ

m to about 30 μ

m.

452. The delivery device of claim 431, further comprising at least one cuff member, wherein the at least one cuff member includes a plurality of lobes, the at least one cuff member configured to at least partially block the nasal cavity of the subject.

453. The delivery device of claim 431, wherein the delivery unit is configured to deliver the substance to the nozzle in response to the flow of exhalation breath.